Nottinghamshire Live on MSN

Man died due to undiagnosed condition on same day he was discharged from QMC

A number of inquests concerning people who died from undiagnosed aortic dissections at Nottingham University Hospitals have ...

Anteris DurAVR® THV Demonstrates Favorable Hemodynamics in Small Annuli Patients with no Valve Related Mortality at One Year

DurAVR ® THV delivered a favorable hemodynamic profile sustained to one-year, with an EOA of 2.1 + 0.2 cm 2 and a mean pressure gradient (MPG) of 8.6 + 2.6 mmHg. At one-year, clinical safety outcomes ...

Anteris Technologies Announces One-Year Clinical Outcomes for DurAVR® THV to be Presented at TCT® 2025

Anteris Technologies Global Corp. (Anteris or the Company) (NASDAQ: AVR, ASX: AVR), a global structural heart company committed to designing, developing, and commercializing cutting-edge medical ...
Medpage Today on MSN

First 7-Year Report of Low-Risk TAVR Reassures, With Finish Line Now in Sight

SAN FRANCISCO -- Long-term outcomes after transcatheter aortic valve replacement (TAVR) were looking more and more like those ...

Anteris Technologies Announces First Patients Treated in DurAVR® THV Global Pivotal Trial (the “PARADIGM Trial”)

MINNEAPOLIS, United States and BRISBANE, Australia, Oct. 27, 2025 (GLOBE NEWSWIRE) -- Anteris Technologies Global Corp. (Anteris or the Company) (NASDAQ: AVR, ASX: AVR) a global structural heart ...
Healio

Q&A: Start with ‘lowest hanging fruit’ to improve cardiac rehab for women

Cardiac rehabilitation improves function and survival after an event, yet women experience less referral and engagement rates ...
TipRanks on MSN

Anteris Technologies Announces Share Sale Agreement

Anteris Technologies Global Corp. ( ($AVR) ) just unveiled an update. On October 23, 2025, Anteris Technologies Global Corp. announced agreements ...

EXCLUSIVE: Baby With Severe Heart Defect Saved by 'Mind-Blowing' In-Utero Heart Surgery

Brooks Klingsporn received a cutting-edge in-utero cardiac surgery while in the womb to treat a life-threatening heart defect ...
TipRanks on MSN

Anteris Technologies Begins Global PARADIGM Trial Enrollment

The latest update is out from Anteris Technologies Global Corp. ( ($AVR) ). On October 27, 2025, Anteris Technologies announced the successful ...

Anteris Technologies Global Corp.: Anteris Technologies Announces First Patients Treated in DurAVR THV Global Pivotal Trial (the "PARADIGM Trial")

MINNEAPOLIS, United States and BRISBANE, Australia, Oct. 27, 2025 (GLOBE NEWSWIRE) -- Anteris Technologies Global Corp. (Anteris or the Company) (NASDAQ: AVR, ASX: AVR) a global structural heart compa ...